ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

HIF-PHIs Offer Hope for Anemia in CKD

November 06, 2021 | 12:45 PM - 01:45 PM

Location: Simulive, Virtual Only

Session Description

Anemia is a common complication of CKD, affecting approximately 5.7 million people with CKD in the United States alone. Left untreated, anemia is associated with diminished quality of life and increased morbidity and mortality in people with CKD.

A newer treatment option for anemia is oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), developed in line with Nobel Prize-winning science. These agents work by stimulating the body's erythropoietin production. This leads to increased red blood cell production and subsequent improvement in iron usage and oxygen delivery to tissues.

Alternatively, erythropoiesis-stimulating agents (ESAs) have a long history of clinical application. They are shown to significantly improve the quality of life of patients with CKD, have good safety profiles, and have been the standard of treatment for anemia in patients with CKD for many years. In this symposium, experts debate which therapy to use and for whom.

Support is provided by an educational grant from Akebia Therapeutics, Inc., and Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Describe the modes of action of ESAs and HIF-PHIs
  • Discuss the safety profiles of ESAs and HIF-PHIs
  • Discuss accumulating evidence for the use of ESAs and HIF-PHIs

Learning Pathway(s)

  • Chronic Kidney Disease

Moderator

  • Tetsuhiro Tanaka, MD, PhD, FASN

Presentations

  • Introduction: Overview of Anemia in CKD
    12:45 PM - 12:55 PM
    Tetsuhiro Tanaka, MD, PhD, FASN
  • HIF-PHIs for the Treatment of Anemia in CKD: Ready for Broad Use
    12:55 PM - 01:20 PM
    Daniel W. Coyne, MD
  • HIF-PHIs for the Treatment of Anemia in CKD: Not So Fast!
    01:20 PM - 01:45 PM